Neuropace Inc
NASDAQ:NPCE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Neuropace Inc
Stock-Based Compensation
Neuropace Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neuropace Inc
NASDAQ:NPCE
|
Stock-Based Compensation
$11.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Stock-Based Compensation
$299m
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Stock-Based Compensation
$158.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
12%
|
|
|
Stryker Corp
NYSE:SYK
|
Stock-Based Compensation
$243m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Stock-Based Compensation
$664m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Stock-Based Compensation
$788.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
Neuropace Inc
Glance View
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.
See Also
What is Neuropace Inc's Stock-Based Compensation?
Stock-Based Compensation
11.1m
USD
Based on the financial report for Dec 31, 2025, Neuropace Inc's Stock-Based Compensation amounts to 11.1m USD.
What is Neuropace Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
52%
Over the last year, the Stock-Based Compensation growth was 8%. The average annual Stock-Based Compensation growth rates for Neuropace Inc have been 10% over the past three years , 52% over the past five years .
